Vaginal Protection and Immunity after Oral Immunization of Mice with a Novel Vaccine Strain ofListeria monocytogenesExpressing Human Immunodeficiency Virus Type 1gag
- 15 September 2006
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (18) , 8880-8890
- https://doi.org/10.1128/jvi.00894-06
Abstract
Natural transmission of human immunodeficiency virus (HIV) occurs at mucosal surfaces. During acute infection, intestinal and other mucosae are preferential sites of virus replication and rapidly become depleted of CD4(+) T cells. Therefore, mucosal immunity may be critical to control both initial infection and the massive early spread of virus. An attenuated D-alanine-requiring strain of the oral intracellular microorganism Listeria monocytogenes expressing HIV type 1 gag was shown to induce protective cell-mediated immunity in mice against viruses that express HIV gag when immunization occurs in the presence of a transient supply of D-alanine. In this study, we examined the efficacy of new attenuated strains that are able to synthesize d-alanine from a heterologous dal gene tightly regulated by an actA-promoted resolvase recombination system. In the absence of d-alanine, Gag-specific cytotoxic T lymphocytes (CTLs) were induced systemically after intravenous immunization, and one strain, Lmdd-gag/pARS, induced strong dose-dependent Gag-specific CTLs after oral immunization. A significant level of Gag-specific CD8(+) T cells was induced in the mucosal-associated lymphoid tissues (MALTs). Upon intravaginal challenge of these orally immunized mice with recombinant vaccinia virus (rVV) expressing HIV gag, gamma interferon- and tumor necrosis factor alpha-secreting Gag-specific CD8(+) T cells were dramatically increased in the spleen and MALTs. Oral immunization with Lmdd-gag/pARS led to complete protection against vaginal challenge by a homologous clade B gag-expressing rVV. In addition, strong cross-clade protection was seen against clades A and C and partial protection against clade G gag-expressing rVV. These results suggest that Lmdd-gag/pARS may be considered as a novel vaccine candidate for use against HIV/AIDS.Keywords
This publication has 61 references indexed in Scilit:
- Cross‐Reactivity of Anti–HIV‐1 T Cell Immune Responses among the Major HIV‐1 Clades in HIV‐1–Positive Individuals from 4 ContinentsThe Journal of Infectious Diseases, 2005
- Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cellsNature, 2005
- CD8+T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG OligodeoxynucleotidesJournal of Virology, 2005
- Complete Protection of Neonatal Rhesus Macaques against Oral Exposure to Pathogenic Simian‐Human Immunodeficiency Virus by Human Anti‐HIV Monoclonal AntibodiesThe Journal of Infectious Diseases, 2004
- Anti-human immunodeficiency virus-gag CD8+ memory T cells generated in vitro from Listeria-immunized miceImmunology, 2003
- Mucosal Immunization with Inactivated Human Immunodeficiency Virus plus CpG Oligodeoxynucleotides Induces Genital Immune Responses and Protection against Intravaginal ChallengeThe Journal of Infectious Diseases, 2002
- Safety and Immunogenicity in Neonatal Mice of a HyperattenuatedListeriaVaccine Directed against Human Immunodeficiency VirusJournal of Virology, 2002
- Systemic Immunity and Mucosal Immunity Are Induced against Human Immunodeficiency Virus Gag Protein in Mice by a New Hyperattenuated Strain ofListeria monocytogenesJournal of Virology, 2001
- Immunity to Intracellular BacteriaAnnual Review of Immunology, 1993
- Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes.The Journal of cell biology, 1989